Company: INDP
Filing Date: 2025-09-02
Form Type: S-1
Source: 0001493152-25-012531
Chunk: 20

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: S-1
Chunk 20
---
ization as of June 30, 2025 as follows:

| ● | on                   
 an actual basis; and |

| ● | on a  pro forma basis to reflect the issuance                                                                     
 of 501,566 shares of common stock, pre-funded warrants to purchase 190,795 shares of common stock and warrants    
 to purchase 1,467,805 shares of our common stock, following the automatic conversion of the June 2025 convertible 
 notes, assuming exercise in full of the pre-funded warrants but no exercise of the warrants (the “Pro             
 Forma Adjustments”); and                                                                                          |

| ● | on a pro forma as adjusted basis to further reflect the                                                                            
 assumed issuance and sale by us of all shares of common stock and accompanying common warrants offered by means of this prospectus 
 at an assumed combined  public offering price of $6.40 per share and accompanying common warrants, which                           
 is based on the last reported sale price of our shares on Nasdaq on August 27, 2025, assuming no sale of pre-funded warrants       
 and after deducting the Placement Agent’s fees and estimated offering expenses payable by us, and without giving effect to         
 the exercise of the common warrants issued in this offering, as if such issuance and sale had occurred on June 30, 2025.           |

The as adjusted information below is illustrative only and our capitalization following the completion of this offering is subject to various adjustments. The as adjusted amounts shown below are unaudited and represent management’s estimate. The information in this table should be read in conjunction with and is qualified by reference to the financial statements and notes thereto and other financial information contained in this prospectus.

|                                                                                              |     | As of June 30, 2025  |         |   |     |                        |         |   |     |                                    |         |   |
|:---------------------------------------------------------------------------------------------|:----|:---------------------|--------:|:--|:----|:-----------------------|--------:|:--|:----|:-----------------------------------|--------:|:--|
| (U.S. dollars in thousands)                                                                  |     | Actual   (unaudited) |         |   |     | Pro Forma  (unaudited) |         |   |     | Pro Forma As Adjusted  (unaudited) |         |   |
| Cash and cash equivalents                                                                    |     | $                    |   6,158 |   |     | $                      |